BRCA1 and ovarian carcinoma: On the other hand, genomic studies revealed a significantly lower risk of ovarian cancer, both with and without BRCA1/2 mutation carriers, in the statin group (OR 0.60; 95% CI 0.43–0.83; p = 0.002 vs. OR 0.69; 95% CI 0.51–0.93; p = 0.01) [120].